推进特发性肺纤维化的药物研发：未来已来。 - Suppr

Suppr

超能文献

Advancing Drug Development in Idiopathic Pulmonary Fibrosis: Tomorrow Is Now.

作者信息

Khor Yet H, Ryerson Christopher J

机构信息

Respiratory Research@Alfred.

School of Translational Medicine Monash University Melbourne, Victoria, Australia.

出版信息

Am J Respir Crit Care Med. 2024 May 1;209(9):1060-1062. doi: 10.1164/rccm.202402-0381ED.

DOI:10.1164/rccm.202402-0381ED

PMID:38484134

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11092962/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6be0/11092962/aa80ff5216a3/rccm.202402-0381EDf1.jpg

相似文献

Advancing Drug Development in Idiopathic Pulmonary Fibrosis: Tomorrow Is Now.推进特发性肺纤维化的药物研发：未来已来。

Am J Respir Crit Care Med. 2024 May 1;209(9):1060-1062. doi: 10.1164/rccm.202402-0381ED.

Drug discovery and development in idiopathic pulmonary fibrosis: challenges and opportunities.特发性肺纤维化的药物发现与开发：挑战与机遇

Drug Discov Today. 2020 Dec;25(12):2277-2283. doi: 10.1016/j.drudis.2020.09.019. Epub 2020 Sep 30.

A Long and Winding Road: Drug Development in Idiopathic Pulmonary Fibrosis.一条漫长而曲折的道路：特发性肺纤维化的药物研发

Am J Respir Crit Care Med. 2024 May 1;209(9):1072-1073. doi: 10.1164/rccm.202402-0290VP.

Long-term treatment of patients with idiopathic pulmonary fibrosis with nintedanib: results from the TOMORROW trial and its open-label extension.尼达尼布治疗特发性肺纤维化患者的长期疗效：来自 TOMORROW 试验及其开放标签扩展研究的结果。

Thorax. 2018 Jun;73(6):581-583. doi: 10.1136/thoraxjnl-2016-209701. Epub 2017 Oct 9.

What have we learned from basic science studies on idiopathic pulmonary fibrosis?特发性肺纤维化的基础科学研究给我们带来了什么启示？

Eur Respir Rev. 2019 Sep 11;28(153). doi: 10.1183/16000617.0029-2019. Print 2019 Sep 30.

Three wishes for improving clinical drug development in pulmonary fibrosis.改善肺纤维化临床药物研发的三个愿望。

Eur Respir J. 2023 Mar 2;61(3). doi: 10.1183/13993003.02355-2022. Print 2023 Mar.

Design of Idiopathic Pulmonary Fibrosis Clinical Trials in the Era of Approved Therapies.获批疗法时代特发性肺纤维化临床试验的设计

Am J Respir Crit Care Med. 2019 Jul 15;200(2):133-139. doi: 10.1164/rccm.201903-0592PP.

Screening of Inhibitors Targeting Heat Shock Protein 47 Involved in the Development of Idiopathic Pulmonary Fibrosis.靶向热休克蛋白 47 治疗特发性肺纤维化的抑制剂筛选。

ChemMedChem. 2021 Aug 19;16(16):2515-2523. doi: 10.1002/cmdc.202100064. Epub 2021 May 19.

Idiopathic pulmonary fibrosis: Disease mechanisms and drug development.特发性肺纤维化：疾病机制与药物研发。

Pharmacol Ther. 2021 Jun;222:107798. doi: 10.1016/j.pharmthera.2020.107798. Epub 2020 Dec 24.

Shedding light on developmental drugs for idiopathic pulmonary fibrosis.揭示特发性肺纤维化治疗药物的研发进展。

Expert Opin Investig Drugs. 2020 Aug;29(8):797-808. doi: 10.1080/13543784.2020.1782885. Epub 2020 Jun 24.

引用本文的文献

A systematic review of the role of quantitative CT in the prognostication and disease monitoring of interstitial lung disease.定量CT在间质性肺疾病预后评估和疾病监测中作用的系统评价

Eur Respir Rev. 2025 Apr 30;34(176). doi: 10.1183/16000617.0194-2024. Print 2025 Apr.

本文引用的文献

Zinpentraxin Alfa for Idiopathic Pulmonary Fibrosis: The Randomized Phase III STARSCAPE Trial.锌结合内肽酶 Alfa 治疗特发性肺纤维化：随机 III 期 STARSCAPE 试验。

Am J Respir Crit Care Med. 2024 May 1;209(9):1132-1140. doi: 10.1164/rccm.202401-0116OC.

Meaningful Endpoints for Idiopathic Pulmonary Fibrosis (IPF) Clinical Trials: Emphasis on 'Feels, Functions, Survives'. Report of a Collaborative Discussion in a Symposium with Direct Engagement from Representatives of Patients, Investigators, the National Institutes of Health, a Patient Advocacy Organization, and a Regulatory Agency.特发性肺纤维化（IPF）临床试验的有意义终点：强调“感觉、功能、生存”。在一次研讨会上的合作讨论报告，患者代表、研究者、美国国立卫生研究院、一个患者权益倡导组织和一个监管机构直接参与了此次研讨会。

Am J Respir Crit Care Med. 2024 Mar 15;209(6):647-669. doi: 10.1164/rccm.202312-2213SO.

Exploring computer-based imaging analysis in interstitial lung disease: opportunities and challenges.探索基于计算机的间质性肺疾病成像分析：机遇与挑战。

ERJ Open Res. 2023 Jul 3;9(4). doi: 10.1183/23120541.00145-2023. eCollection 2023 Jul.

Eligibility criteria from pharmaceutical randomised controlled trials of idiopathic pulmonary fibrosis: a registry-based study.特发性肺纤维化的药物随机对照试验的入选标准：基于登记的研究。

Eur Respir J. 2023 May 5;61(5). doi: 10.1183/13993003.02163-2022. Print 2023 May.

GLPG1205 for idiopathic pulmonary fibrosis: a phase 2 randomised placebo-controlled trial.GLPG1205 治疗特发性肺纤维化：一项 2 期随机安慰剂对照试验。

Eur Respir J. 2023 Mar 2;61(3). doi: 10.1183/13993003.01794-2022. Print 2023 Mar.

Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline.特发性肺纤维化（更新版）和成人进展性肺纤维化：美国胸科学会/欧洲呼吸学会/日本呼吸学会/拉丁美洲胸科学会临床实践指南。

Am J Respir Crit Care Med. 2022 May 1;205(9):e18-e47. doi: 10.1164/rccm.202202-0399ST.

Diagnostic Accuracy of Endobronchial Optical Coherence Tomography for the Microscopic Diagnosis of Usual Interstitial Pneumonia.经支气管光学相干断层成像术对寻常型间质性肺炎的微观诊断的准确性。

Am J Respir Crit Care Med. 2021 Nov 15;204(10):1164-1179. doi: 10.1164/rccm.202104-0847OC.

Patient-centered Outcomes Research in Interstitial Lung Disease: An Official American Thoracic Society Research Statement.以患者为中心的间质性肺疾病结局研究：美国胸科学会官方研究声明。

Am J Respir Crit Care Med. 2021 Jul 15;204(2):e3-e23. doi: 10.1164/rccm.202105-1193ST.

Fibrosis: from mechanisms to medicines.纤维化：从机制到药物

Nature. 2020 Nov;587(7835):555-566. doi: 10.1038/s41586-020-2938-9. Epub 2020 Nov 25.

Standardization of Spirometry 2019 Update. An Official American Thoracic Society and European Respiratory Society Technical Statement.肺功能测定标准化 2019 修订版。美国胸科学会和欧洲呼吸学会官方技术声明。

Am J Respir Crit Care Med. 2019 Oct 15;200(8):e70-e88. doi: 10.1164/rccm.201908-1590ST.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验